MedTrace Logo

Prospective Study of the Prognostic Value of New Markers in Adults With ALK-positive Large Anaplastic Lymphoma

NCT03603847 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 41

Last updated 2023-09-26

No results posted yet for this study

Summary

The study aims to evaluate the prognostic value on the complete metabolic response rate (MCR), the incidence of relapse / progression, the Progression Free Survival (PFS) and the Overall Survival (OS).

* at diagnosis
* after the first cycle of CHOEP (early evaluation)
* at the end of treatment

Conditions

  • Anaplastic Large Cell Lymphoma, ALK-Positive

Sponsors & Collaborators

  • Hôpital Necker-Enfants Malades

    collaborator OTHER

  • Fondation ARC

    collaborator OTHER

  • Pfizer

    collaborator INDUSTRY

  • Takeda

    collaborator INDUSTRY

  • The Lymphoma Academic Research Organisation

    lead OTHER

Principal Investigators

  • David SIBON, MD · Hôpital Necker-Enfants Malades

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-02
Primary Completion
2023-06-16
Completion
2023-06-16

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03603847 on ClinicalTrials.gov